Published in J Clin Oncol on August 29, 2005
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer (2006) 1.45
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15
Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice. Cancer Epidemiol Biomarkers Prev (2012) 1.08
A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol (2009) 1.06
Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst (2014) 1.02
Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health (2014) 1.02
Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res (2011) 0.97
Factors influencing cancer risk perception in high risk populations: a systematic review. Hered Cancer Clin Pract (2011) 0.93
Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control (2012) 0.93
Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer (2011) 0.92
New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy. Clin Cancer Res (2010) 0.92
Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer (2011) 0.92
BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Res Treat (2010) 0.92
Cognitive behavioral therapy and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: design of a multicenter trial. BMC Womens Health (2009) 0.90
Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer. Fam Cancer (2013) 0.89
Challenging and complex decisions in the management of the BRCA mutation carrier. J Womens Health (Larchmt) (2013) 0.89
Oophorectomy: the debate between ovarian conservation and elective oophorectomy. Menopause (2013) 0.84
Pharmacologically induced hypogonadism and sexual function in healthy young women and men. Neuropsychopharmacology (2008) 0.83
Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. Br J Cancer (2011) 0.83
What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo-oophorectomy. Fam Cancer (2011) 0.83
Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. Fam Cancer (2013) 0.81
Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Fam Cancer (2012) 0.81
Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers. Hered Cancer Clin Pract (2014) 0.80
Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res (Phila) (2015) 0.80
Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Fam Cancer (2008) 0.79
Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer (2010) 0.78
Unmet support needs and distress among women with a BRCA1/2 mutation. Fam Cancer (2013) 0.78
Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. Fam Cancer (2015) 0.77
Relationship satisfaction predicts sexual activity following risk-reducing salpingo-oophorectomy. J Psychosom Obstet Gynaecol (2014) 0.77
Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer. Oncologist (2011) 0.77
Are we ready for online tools in decision making for BRCA1/2 mutation carriers? J Clin Oncol (2012) 0.76
The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. Fam Cancer (2015) 0.75
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol (2017) 0.75
Understanding the needs of women considering risk-reducing salpingo-oophorectomy. Cancer Nurs (2013) 0.75
Is the fault in our steroids or in our selves? J Clin Oncol (2006) 0.75
The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review. BMC Womens Health (2017) 0.75
The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause. Fam Cancer (2012) 0.75
The Angelina Jolie Effect in Jewish Law: Prophylactic Mastectomy and Oophorectomy in BRCA Carriers. Rambam Maimonides Med J (2015) 0.75
Quality or quantity in the management of hereditary ovarian cancer risk: Is it really a trade-off? J Clin Oncol (2005) 0.75
Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act. Oncologist (2017) 0.75
Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors. BMC Cancer (2016) 0.75
Sexual health needs and educational intervention preferences for women with cancer. Breast Cancer Res Treat (2017) 0.75
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA (2002) 5.30
Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res (2004) 4.33
Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med (2008) 4.33
Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol (2008) 3.75
POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer (2004) 2.89
Physical exercise in cancer patients during and after medical treatment: a systematic review of randomized and controlled clinical trials. J Clin Oncol (2005) 2.71
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol (2006) 2.57
Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes (2006) 2.48
The Group-Based Medical Mistrust Scale: psychometric properties and association with breast cancer screening. Prev Med (2004) 2.48
Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res (2011) 2.42
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol (2009) 2.35
The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol (2002) 2.25
Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol (2008) 2.23
Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol (2013) 2.19
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Perceived disadvantages and concerns about abuses of genetic testing for cancer risk: differences across African American, Latina and Caucasian women. Patient Educ Couns (2003) 2.03
Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol (2003) 2.00
Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer (2002) 1.98
Intraoperative near infrared fluorescence guided identification of the ureters using low dose methylene blue: a first in human experience. J Urol (2013) 1.97
The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer (2005) 1.97
ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res (2013) 1.96
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer (2008) 1.95
Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol (2005) 1.93
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol (2014) 1.91
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol (2010) 1.84
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer (2010) 1.84
A systematic review of web-based interventions for patient empowerment and physical activity in chronic diseases: relevance for cancer survivors. J Med Internet Res (2013) 1.82
Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol (2012) 1.68
Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev (2002) 1.68
Effectiveness of behavioral techniques and physical exercise on psychosocial functioning and health-related quality of life in breast cancer patients and survivors--a meta-analysis. Psychooncology (2011) 1.68
Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer (2007) 1.62
Comparing higher order models for the EORTC QLQ-C30. Qual Life Res (2011) 1.60
HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol (2006) 1.59
Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J Clin Oncol (2007) 1.58
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer (2010) 1.57
The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy. Eur J Nucl Med Mol Imaging (2004) 1.56
Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. J Clin Epidemiol (2006) 1.55
The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol (2006) 1.55
Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene (2003) 1.52
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer (2011) 1.52
Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology (2009) 1.51
Health related quality of life in men with prostate cancer. J Urol (2003) 1.51
The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey. Gynecol Oncol (2005) 1.49
Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. J Cancer Surviv (2014) 1.49
Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level? Menopause (2011) 1.48
Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study. Cancer (2008) 1.47
TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst (2004) 1.45
Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma. Gynecol Oncol (2004) 1.45
Experiences of racist events are associated with negative health consequences for African American women. J Natl Med Assoc (2003) 1.44
Comparing bivalent and quadrivalent HPV vaccines. BMJ (2011) 1.43
The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol (2006) 1.41
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers. Endocr Relat Cancer (2012) 1.40
Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology (2005) 1.39
The Value of Endocervical Curettage in Addition to Biopsies in Women Referred to Colposcopy. J Low Genit Tract Dis (2015) 1.39
Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer (2007) 1.37
Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2003) 1.36
Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol (2011) 1.34
Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer (2011) 1.34
Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res (2013) 1.33
Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol (2004) 1.33
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol (2003) 1.31
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30
Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol (2009) 1.30
Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer (2007) 1.27
Use of patient-reported outcomes in clinical practice. Lancet (2009) 1.25
Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study. Eur Arch Otorhinolaryngol (2007) 1.24
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol (2005) 1.24
Optimization of near-infrared fluorescent sentinel lymph node mapping in cervical cancer patients. Int J Gynecol Cancer (2011) 1.22
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat (2010) 1.20
Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer (2006) 1.20
The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol (2010) 1.19
Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children. Genet Test (2007) 1.16
Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer (2007) 1.16
Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol (2009) 1.16
The psychometric and clinical validity of the SWAL-QOL questionnaire in evaluating swallowing problems experienced by patients with oral and oropharyngeal cancer. Oral Oncol (2009) 1.12
The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer (2011) 1.12